These findings highlight the potential of combining Gys1 ASO with ERT as a promising therapeutic strategy for Pompe disease, overcoming tissue‐specific limitations and supporting overall cellular function. Here, ELF3 is linked to Glycogen storage disease due to acid maltase deficiency.